ReviewAdvances in therapy2016
25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives.
Review in Advances in therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Evolving Characteristics of Gadolinium-Based Contrast Agents for MR Imaging: A Systematic Review of the Importance of Relaxivity.Journal of magnetic resonance imaging : JMRI · 2025Pooled it
- CSF enhancement on post-contrast fluid-attenuated inversion recovery images; a systematic review.NeuroImage. Clinical · 2020Pooled it
- EPR-based Assessment of Gadolinium-based Contrast Agent Retention and Gadolinium Transchelation in Inflamed Murine Brain.Investigative radiology · 2026Article
- Machine Learning-Based Development of Gadolinium Binding Peptides.NMR in biomedicine · 2026Article
- Deep learning for synthetic contrast-enhanced CT and MRI: a scoping review.European radiology · 2026Article
- Gadoquatrane in Contrast-enhanced Head-and-neck and Liver Magnetic Resonance Imaging: A Preclinical Dose-Response Study in Pigs.Investigative radiology · 2026Article
- Artificial intelligence-amplified contrast enhancement in brain magnetic resonance imaging for improving image quality and lesion visualization: a prospective pilot study.Quantitative imaging in medicine and surgery · 2026Article
- Deep learning for contrast-enhanced MRI in pediatric brain imaging.Neuroradiology · 2026Article
- Advancements in Cardiac Magnetic Resonance Imaging: Innovations, Challenges, and Future Directions.Reviews in cardiovascular medicine · 2026Review
- Dynamic Contrast Enhanced-Magnetic Resonance Fingerprinting (DCE-MRF) Improves Detection of Induced Vascular Perfusion Reduction in a Mouse Breast Cancer Model.Magnetic resonance in medicine · 2026Article
- Gadolinium-based contrast agents in pediatric MRI: renal safety, risk mitigation, and emerging alternatives.Pediatric radiology · 2026Review
- Brain Tumor Imaging with Iopamidol CEST MRI: In Vivo Detection and Validation.Chemical & biomedical imaging · 2026Article
- Spin State Modulation Strategies for Transition Metal-Based MRI Contrast Agents.Chemical & biomedical imaging · 2026Review
- Magnetic nanoparticle contrast agents for MRI: structure-property relationships,Nanotechnology · 2026Review
- Gadolinium Pollution-A Future Forward Perspective on Human and Environmental Impact.Magnetic resonance in medicine · 2026Review
- Active radiologist role in contrast administration during MRI follow-up of soft tissue sarcoma reduces gadolinium usage: a cost-saving analysis study.Irish journal of medical science · 2026Article
- Impact of Contrast Agent Viscosity and Fallopian Tube Inner Diameter on Tubal Visualization in MR Hysterosalpingography: A Phantom StudyCurrent medical imaging · 2026Article
- Convergent Evolution: Self-Assembly of Small Molecule, Polymeric, and Inorganic Contrast Agents toward Advanced MRI.Journal of the American Chemical Society · 2025Review
- Machine learning-based development of Gadolinium binding peptides.bioRxiv : the preprint server for biology · 2025Article
- Review
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledIn 1988, the first contrast agent specifically designed for magnetic resonance imaging (MRI), gadopentetate dimeglumine (Magnevist(®)), became available for clinical use. Since then, a plethora of studies have investigated the potential of MRI contrast agents for diagnostic imaging across the body, including the central nervous system, heart and circulation, breast, lungs, the gastrointestinal, genitourinary, musculoskeletal and lymphatic systems, and even the skin. Today, after 25 years of contrast-enhanced (CE-) MRI in clinical practice, the utility of this diagnostic imaging modality has expanded beyond initial expectations to become an essential tool for disease diagnosis and management worldwide. CE-MRI continues to evolve, with new techniques, advanced technologies, and novel contrast agents bringing exciting opportunities for more sensitive, targeted imaging and improved patient management, along with associated clinical challenges. This review aims to provide an overview on the history of MRI and contrast media development, to highlight certain key advances in the clinical development of CE-MRI, to outline current technical trends and clinical challenges, and to suggest some important future perspectives.
fundingBayer HealthCare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.